Applied DNA’s SigNature® DNA Evidence Helps to Convict Over 131 Criminals to Date
Sentencing for Criminals Now Tops 625 Years
Applied DNA Sciences Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing,
is pleased to report that SigNature DNA evidence has resulted in over 131 convictions, with sentences of 625 years to date, and
many more cases in the pipeline.
The confirmed number of convictions and sentencing are received from law enforcement officers. Due to internal protocols in some
European countries, we do not always receive confirmation of the outcome of criminal investigations; for that reason, we estimate
the actual numbers to be significantly higher.
The crimes we help solve with the aid of our SigNature DNA products include attacks against armored car companies, whose
activity is commonly known across Europe as “Cash-and-Valuables-in-Transit.” Other types of crimes whose conviction benefits from
Applied DNA’s technology include theft of
entire vehicles and their components, Automated Teller Machine (ATM) burglary, and theft of goods from businesses and private
residences.
The longest-serving distributor of Applied DNA’s security products, SmartDNA Protection Nordic AB, recently won an award from
Deloitte Sweden Technology Fast 50, who recognize the region’s fastest-growing technology companies.
Tony Benson, Managing Director EMEA, commented, “We are very active across Europe working with industry and Law Enforcement
agencies to help the fight against crime using a well-known, fundamental security principle of ‘Detect, Deter, Defend’. The
criminals involved range from low-level burglars to highly-organized and violent criminals with global distribution
capabilities.”
One of the robberies in question was solved in part due to the discovery of dye-stained cash found in the criminal’s home. This
dye contained a unique SigNature DNA tag which definitively connected the stained notes to the cash box that was stolen from
unarmed security guards as they refilled cash machines.
Benson added, “Law Enforcement agencies are very satisfied with the high quality and speed of service we provide. We commit to a
10-day turnaround time from receipt of forensic samples to the issuance of an Expert Witness Report, and we always meet or exceed
this commitment. For the last 3 years, our average turnaround time has been 7 days, which we believe is best-in-class by a country
mile. We attribute this excellence to the professionalism and dedication of our Forensics team, led by Dr. Ila Lansky.
Dr. Lansky, Director of Forensics, added: ”We recognize the importance of providing accurate and quick service to Law
Enforcement agencies, who are often up against deadlines to release suspects on bail. In some countries, suspects skip bail on a
regular basis. The Expert Witness Reports we produce and support in occasional court appearances are detailed, accurate, thoroughly
documented and accepted by courts around the world. DNA evidence is often featured on “Crime Scene Investigation” programs, and
therefore easily explained to the layperson, facilitating its use and strength in conviction.”
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and DNA mass production for diagnostics and therapeutics.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit
adnas.com for more information. Follow us on
Twitter and
LinkedIn. Join our
mailing list.
The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of
Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources,
limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including
whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process,
including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign
regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our
Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018,
May 3, 2018 and August 13, 2018, which are available at
www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events
or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20181126005131r1&sid=mstr3&distro=nx&lang=en)
Investor contact:
Sanjay M. Hurry, LHA Investor Relations
212-838-3777
shurry@lhai.com
Media contact:
Cheryl Schneider, DGI Comm
212-825-3210
cschneider@dgicomm.com
Program contact:
Tony Benson, 44 (0) 7552 429341
tony.benson@adnas.com
Web:
www.adnas.com
Twitter: @APDN
View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005131/en/